Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

Dow Jones01-29

By Billy Gray

Sanofi said it would execute a 1 billion-euro ($1.20 billion) share buyback program this year, and posted a rise in fourth-quarter sales.

The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency. Business operating profit--one of the company's preferred metrics, which strips out exceptional items--rose 12.7% to 2.34 billion euros compared with the prior-year period.

Analysts had expected 11.14 billion euros in sales and business operating profit of 2.37 billion euros for the quarter, according to consensus estimates provided by Vara Research.

Investors have been scrutinizing the strength of Sanofi's pipeline in light of recent trial setbacks that were especially disappointing given the imminent loss of patent exclusivity for its blockbuster drug Dupixent. Houman Ashrafian, head of research and development, said in a call with reporters that 2025 was clearly a mixed year.

The group has turned to deals to bolster its sizeable vaccine portfolio, including its $2.2 billion acquisition of vaccine specialist Dynavax Technologies in December.

Sanofi forecast 2026 sales to grow by a high single-digit percentage, and business earnings per share to grow slightly faster than sales, both at constant exchange rates.

Write to Billy Gray at william.gray@wsj.com

(END) Dow Jones Newswires

January 29, 2026 06:20 ET (11:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607086561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607086561","market":"fut","top_or_hot":-1,"title":"Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Billy Gray \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> said it would execute a 1 billion-euro ($1.20 billion) share buyback program this year, and posted a rise in fourth-quarter sales. \n</p>\n<p>\n  The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency. Business operating profit--one of the company's preferred metrics, which strips out exceptional items--rose 12.7% to 2.34 billion euros compared with the prior-year period. \n</p>\n<p>\n  Analysts had expected 11.14 billion euros in sales and business operating profit of 2.37 billion euros for the quarter, according to consensus estimates provided by Vara Research. \n</p>\n<p>\n  Investors have been scrutinizing the strength of <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s pipeline in light of recent trial setbacks that were especially disappointing given the imminent loss of patent exclusivity for its blockbuster drug Dupixent. Houman Ashrafian, head of research and development, said in a call with reporters that 2025 was clearly a mixed year. \n</p>\n<p>\n  The group has turned to deals to bolster its sizeable vaccine portfolio, including its $2.2 billion acquisition of vaccine specialist Dynavax Technologies in December. \n</p>\n<p>\n  Sanofi forecast 2026 sales to grow by a high single-digit percentage, and business earnings per share to grow slightly faster than sales, both at constant exchange rates. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Billy Gray at william.gray@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 06:20 ET (11:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-29 19:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Billy Gray \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> said it would execute a 1 billion-euro ($1.20 billion) share buyback program this year, and posted a rise in fourth-quarter sales. \n</p>\n<p>\n  The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency. Business operating profit--one of the company's preferred metrics, which strips out exceptional items--rose 12.7% to 2.34 billion euros compared with the prior-year period. \n</p>\n<p>\n  Analysts had expected 11.14 billion euros in sales and business operating profit of 2.37 billion euros for the quarter, according to consensus estimates provided by Vara Research. \n</p>\n<p>\n  Investors have been scrutinizing the strength of <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s pipeline in light of recent trial setbacks that were especially disappointing given the imminent loss of patent exclusivity for its blockbuster drug Dupixent. Houman Ashrafian, head of research and development, said in a call with reporters that 2025 was clearly a mixed year. \n</p>\n<p>\n  The group has turned to deals to bolster its sizeable vaccine portfolio, including its $2.2 billion acquisition of vaccine specialist Dynavax Technologies in December. \n</p>\n<p>\n  Sanofi forecast 2026 sales to grow by a high single-digit percentage, and business earnings per share to grow slightly faster than sales, both at constant exchange rates. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Billy Gray at william.gray@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 06:20 ET (11:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607086561","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607086561","pubTimestamp":1769685600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sanofi said it would execute a 1 billion-euro  share buyback program this year, and posted a rise in fourth-quarter sales.The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency. Business operating profit--one of the company's preferred metrics, which strips out exceptional items--rose 12.7% to 2.34 billion euros compared with the prior-year period.Analysts had expected 11.14 billion euros in sales and business operating profit of 2.37 billion euros for the quarter, according to consensus estimates provided by Vara Research.Investors have been scrutinizing the strength of Sanofi's pipeline in light of recent trial setbacks that were especially disappointing given the imminent loss of patent exclusivity for its blockbuster drug Dupixent. Houman Ashrafian, head of research and development, said in a call with reporters that 2025 was clearly a mixed year.The group has turned to deals to bolster its sizeable vaccine portfol","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"赛诺菲在药物管道经历了好坏参半的一年后仍然致力于疫苗——更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"By Billy Gray \n\n\n \n\n\nSanofi said it would execute a 1 billion-euro ($1.20 billion) share buyback program this year, and posted a rise in fourth-quarter sales. \n\n\n  The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency. Business operating profit--one of the company's preferred metrics, which strips out exceptional items--rose 12.7% to 2.34 billion euros compared with the prior-year period. \n\n\n  Analysts had expected 11.14 billion euros in sales and business operating profit of 2.37 billion euros for the quarter, according to consensus estimates provided by Vara Research. \n\n\n  Investors have been scrutinizing the strength of Sanofi's pipeline in light of recent trial setbacks that were especially disappointing given the imminent loss of patent exclusivity for its blockbuster drug Dupixent. Houman Ashrafian, head of research and development, said in a call with reporters that 2025 was clearly a mixed year. \n\n\n  The group has turned to deals to bolster its sizeable vaccine portfolio, including its $2.2 billion acquisition of vaccine specialist Dynavax Technologies in December. \n\n\n  Sanofi forecast 2026 sales to grow by a high single-digit percentage, and business earnings per share to grow slightly faster than sales, both at constant exchange rates. \n\n\n \n\n\n  Write to Billy Gray at william.gray@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 06:20 ET (11:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607086561","isCrawlerRequest":true}